This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results
Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules
Keeping Track: Approval Of First Intranasal Naloxone Copycat Highlights Otherwise Generic Week
Life After FDA: Rachel Sherman To Tackle Real World Evidence, Clinical Trial Efficiency